US Patent

US9283219 — Sublingual films

Method of Use · Assigned to Cynapsus Therapeutics Inc · Expires 2030-06-11 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects sublingual film formulations of dopamine agonists for treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders.

USPTO Abstract

The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Drugs covered by this patent

apomorphine-hydrochloride (APOMORPHINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2825`	—	apomorphine-hydrochloride
`U-2825`	—	apomorphine-hydrochloride
`U-2825`	—	apomorphine-hydrochloride
`U-2825`	—	apomorphine-hydrochloride
`U-2825`	—	apomorphine-hydrochloride

Patent Metadata

Patent number: US9283219
Jurisdiction: US
Classification: Method of Use
Expires: 2030-06-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Cynapsus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.